Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Maruggi G, Zhang C, Li J, Ulmer JB, Yu D.

Mol Ther. 2019 Apr 10;27(4):757-772. doi: 10.1016/j.ymthe.2019.01.020. Epub 2019 Feb 7. Review.

PMID:
30803823
2.

Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Samsa MM, Dupuy LC, Beard CW, Six CM, Schmaljohn CS, Mason PW, Geall AJ, Ulmer JB, Yu D.

Mol Ther. 2019 Apr 10;27(4):850-865. doi: 10.1016/j.ymthe.2018.12.013. Epub 2019 Jan 7.

PMID:
30770173
3.

Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection.

Baeza Garcia A, Siu E, Sun T, Exler V, Brito L, Hekele A, Otten G, Augustijn K, Janse CJ, Ulmer JB, Bernhagen J, Fikrig E, Geall A, Bucala R.

Nat Commun. 2018 Jul 13;9(1):2714. doi: 10.1038/s41467-018-05041-7.

4.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

5.

Mechanism of action of mRNA-based vaccines.

Iavarone C, O'hagan DT, Yu D, Delahaye NF, Ulmer JB.

Expert Rev Vaccines. 2017 Sep;16(9):871-881. doi: 10.1080/14760584.2017.1355245. Epub 2017 Jul 28. Review.

PMID:
28701102
6.

Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, Debasitis JC, Maruggi G, Otten GR, Geall AJ, Yu D, Ulmer JB, Iavarone C.

J Immunol. 2017 May 15;198(10):4012-4024. doi: 10.4049/jimmunol.1601877. Epub 2017 Apr 17.

7.

Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Magini D, Giovani C, Mangiavacchi S, Maccari S, Cecchi R, Ulmer JB, De Gregorio E, Geall AJ, Brazzoli M, Bertholet S.

PLoS One. 2016 Aug 15;11(8):e0161193. doi: 10.1371/journal.pone.0161193. eCollection 2016.

8.

Recent innovations in mRNA vaccines.

Ulmer JB, Geall AJ.

Curr Opin Immunol. 2016 Aug;41:18-22. doi: 10.1016/j.coi.2016.05.008. Epub 2016 May 26. Review.

PMID:
27240054
9.

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S.

J Virol. 2015 Oct 14;90(1):332-44. doi: 10.1128/JVI.01786-15. Print 2016 Jan 1.

10.

Self-amplifying mRNA vaccines.

Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ.

Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.

PMID:
25620012
11.

Vaccines 'on demand': science fiction or a future reality.

Ulmer JB, Mansoura MK, Geall AJ.

Expert Opin Drug Discov. 2015 Feb;10(2):101-6. doi: 10.1517/17460441.2015.996128. Epub 2015 Jan 13.

PMID:
25582273
12.

Introduction to RNA-based vaccines and therapeutics.

Geall AJ, Ulmer JB.

Expert Rev Vaccines. 2015 Feb;14(2):151-2. doi: 10.1586/14760584.2015.1001244. Epub 2015 Jan 12. No abstract available.

PMID:
25578187
13.

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, Ulmer JB, Brito LA, Cu Y, Banerjee K, Otten GR, Burke B, Dey A, Heeney JL, Shen X, Tomaras GD, Labranche C, Montefiori DC, Liao HX, Haynes B, Geall AJ, Barnett SW.

J Infect Dis. 2015 Mar 15;211(6):947-55. doi: 10.1093/infdis/jiu522. Epub 2014 Sep 18.

14.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

15.

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.

Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ.

Expert Opin Drug Deliv. 2014 Jun;11(6):885-99. doi: 10.1517/17425247.2014.901308. Epub 2014 Mar 26. Review.

PMID:
24665982
16.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

17.

Vaccine adjuvants: mode of action.

De Gregorio E, Caproni E, Ulmer JB.

Front Immunol. 2013 Jul 31;4:214. doi: 10.3389/fimmu.2013.00214. eCollection 2013.

18.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

19.

RNA: the new revolution in nucleic acid vaccines.

Geall AJ, Mandl CW, Ulmer JB.

Semin Immunol. 2013 Apr;25(2):152-9. doi: 10.1016/j.smim.2013.05.001. Epub 2013 Jun 2. Review.

PMID:
23735226
20.

Therapeutic vaccines and immunotherapies: current challenges and new frontiers.

Oviedo-Orta E, Plotkin SA, Ulmer JB, Ahmed SS.

Expert Rev Vaccines. 2013 Mar;12(3):243-4. doi: 10.1586/erv.13.29. No abstract available.

PMID:
23496662
21.

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.

Cu Y, Broderick KE, Banerjee K, Hickman J, Otten G, Barnett S, Kichaev G, Sardesai NY, Ulmer JB, Geall A.

Vaccines (Basel). 2013 Aug 22;1(3):367-83. doi: 10.3390/vaccines1030367.

22.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

23.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

24.

RNA-based vaccines.

Ulmer JB, Mason PW, Geall A, Mandl CW.

Vaccine. 2012 Jun 22;30(30):4414-8. doi: 10.1016/j.vaccine.2012.04.060. Epub 2012 Apr 28. Review.

PMID:
22546329
25.

Promising cutting-edge technologies and tools to accelerate the discovery and development of new vaccines.

Ulmer JB, Sztein MB.

Curr Opin Immunol. 2011 Jun;23(3):374-6. doi: 10.1016/j.coi.2011.04.004. Epub 2011 Apr 27. No abstract available.

26.

Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic.

Martin G, Burke B, Thaï R, Dey AK, Combes O, Ramos OH, Heyd B, Geonnotti AR, Montefiori DC, Kan E, Lian Y, Sun Y, Abache T, Ulmer JB, Madaoui H, Guérois R, Barnett SW, Srivastava IK, Kessler P, Martin L.

J Biol Chem. 2011 Jun 17;286(24):21706-16. doi: 10.1074/jbc.M111.232272. Epub 2011 Apr 12. Erratum in: J Biol Chem. 2011 Aug 19;286(33):29442. Ramos, Oscar H P [added].

27.

Alum's adjuvant action: grease is the word.

Mbow ML, De Gregorio E, Ulmer JB.

Nat Med. 2011 Apr;17(4):415-6. doi: 10.1038/nm0411-415. No abstract available.

PMID:
21475229
28.

Structure-based antigen design: a strategy for next generation vaccines.

Dormitzer PR, Ulmer JB, Rappuoli R.

Trends Biotechnol. 2008 Dec;26(12):659-67. doi: 10.1016/j.tibtech.2008.08.002. Epub 2008 Oct 30. Review.

PMID:
18977045
29.

A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

Martin G, Sun Y, Heyd B, Combes O, Ulmer JB, Descours A, Barnett SW, Srivastava IK, Martin L.

Virology. 2008 Nov 25;381(2):241-50. doi: 10.1016/j.virol.2008.08.039. Epub 2008 Oct 2.

30.

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, Rabussay D, Zhang L, Ulmer JB, Barnett SW, Donnelly JJ.

AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16. doi: 10.1089/aid.2008.0055.

31.

DNA Vaccines 2008--A marcus evans Forum Bridging the Gap Between Technology and Application.

Ulmer JB.

IDrugs. 2008 May;11(5):322-4. No abstract available.

PMID:
18465669
32.

DNA vaccination.

Ulmer JB, Rappuoli R.

Curr Protoc Hum Genet. 2003 Aug;Chapter 13:Unit 13.2. doi: 10.1002/0471142905.hg1302s37.

PMID:
18428342
33.

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, Barnett SW.

Virology. 2008 Mar 15;372(2):273-90. Epub 2007 Dec 3. Erratum in: Virology. 2008 Nov 25;381(2):287. Diaz-Avalos, Ruben [added].

34.

Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.

Weiss WR, Kumar A, Jiang G, Williams J, Bostick A, Conteh S, Fryauff D, Aguiar J, Singh M, O'Hagan DT, Ulmer JB, Richie TL.

PLoS One. 2007 Oct 24;2(10):e1063.

35.

The road to licensure of a DNA vaccine.

Salonius K, Simard N, Harland R, Ulmer JB.

Curr Opin Investig Drugs. 2007 Aug;8(8):635-41. Review.

PMID:
17668365
36.

DNA vaccines: recent technological and clinical advances.

Ulmer JB, Wahren B, Liu MA.

Discov Med. 2006 Jun;6(33):109-12.

37.

Vaccine manufacturing: challenges and solutions.

Ulmer JB, Valley U, Rappuoli R.

Nat Biotechnol. 2006 Nov;24(11):1377-83.

PMID:
17093488
38.

Role of neutralizing antibodies in protective immunity against HIV.

Srivastava IK, Ulmer JB, Barnett SW.

Hum Vaccin. 2005 Mar-Apr;1(2):45-60. Epub 2005 Mar 17. Review.

PMID:
17038830
39.

Novel vaccines: bridging research, development and production - CHI's Inaugural Conference.

Ulmer JB.

IDrugs. 2006 Oct;9(10):696-8. No abstract available.

PMID:
17016775
40.

Microparticle-based technologies for vaccines.

O'Hagan DT, Singh M, Ulmer JB.

Methods. 2006 Sep;40(1):10-9. Review.

PMID:
16997709
41.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

42.

DNA vaccines for HIV/AIDS.

Ulmer JB, Wahren B, Liu MA.

Curr Opin HIV AIDS. 2006 Jul;1(4):309-13. doi: 10.1097/01.COH.0000232346.08285.a8.

PMID:
19372826
43.

Gene-based vaccines: recent technical and clinical advances.

Ulmer JB, Wahren B, Liu MA.

Trends Mol Med. 2006 May;12(5):216-22. Epub 2006 Apr 18. Review.

PMID:
16621717
44.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
45.

Human clinical trials of plasmid DNA vaccines.

Liu MA, Ulmer JB.

Adv Genet. 2005;55:25-40. Review.

PMID:
16291211
46.

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, Rappuoli R.

Microbes Infect. 2005 Nov;7(14):1386-91. Epub 2005 Sep 20.

PMID:
16275150
47.

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Kong WP, Xu L, Stadler K, Ulmer JB, Abrignani S, Rappuoli R, Nabel GJ.

J Virol. 2005 Nov;79(22):13915-23.

48.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

49.

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.

Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB.

Vaccine. 2006 May 22;24(21):4503-9. Epub 2005 Aug 19.

PMID:
16181711
50.

Mechanisms of action of DNA vaccines.

Selby M, Walker CM, Ulmer JB.

Expert Opin Investig Drugs. 1998 Dec;7(12):1987-95.

PMID:
15991941

Supplemental Content

Loading ...
Support Center